Biolase (BIOL) Misses Q2 EPS by 27c

Biolase (NASDAQ: BIOL) reported Q2 EPS of ($0.91), $0.27 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $10.63 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c